Pier Mannuccio Mannucci

List of Publications by Citations

309 papers	14,102 citations	60 h-index	113 g-index
329 ext. papers	16,002 ext. citations	6.6 avg, IF	7.08 L-index

#	Paper	IF	Citations
309	The coagulopathy of chronic liver disease. *New England Journal of Medicine*, **2011**, 365, 147-56	59.2	935
308	Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. *Journal of Thrombosis and Haemostasis*, **2006**, 4, 2103-14	15.4	884
307	The hemophilias--from royal genes to gene therapy. *New England Journal of Medicine*, **2001**, 344, 1773-9	59.2	747
306	Hemostatic drugs. *New England Journal of Medicine*, **1998**, 339, 245-53	59.2	499
305	Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. *Blood*, **2001**, 98, 2730-5	2.2	425
304	Desmopressin (DDAVP) in the Treatment of Bleeding Disorders: The First 20 Years. *Blood*, **1997**, 90, 2515-2521	2.2	417
303	Treatment of von Willebrand's Disease. *New England Journal of Medicine*, **2004**, 351, 683-94	59.2	390
302	Recessively inherited coagulation disorders. *Blood*, **2004**, 104, 1243-52	2.2	380
301	Prevention and treatment of major blood loss. *New England Journal of Medicine*, **2007**, 356, 2301-11	59.2	373
300	A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). *Journal of Thrombosis and Haemostasis*, **2011**, 9, 700-10	15.4	329
299	Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. *Blood*, **2003**, 102, 2358-63	2.2	314
298	Different Risks of Thrombosis in Four Coagulation Defects Associated With Inherited Thrombophilia: A Study of 150 Families. *Blood*, **1998**, 92, 2353-2358	2.2	307
297	ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. *Blood*, **2005**, 106, 1262-7	2.2	229
296	Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. *Blood*, **2014**, 124, 1715-26	2.2	220
295	Polypharmacy, length of hospital stay, and in-hospital mortality among elderly patients in internal medicine wards. The REPOSI study. *European Journal of Clinical Pharmacology*, **2011**, 67, 507-19	2.8	208
294	Health Effects of Ambient Air Pollution in Developing Countries. *International Journal of Environmental Research and Public Health*, **2017**, 14,	4.6	182
293	Transmission of non-A, non-B hepatitis by heat-treated factor VIII concentrate. *Lancet, The*, **1985**, 2, 1-4	40	154

292	Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP). *British Journal of Haematology*, **1992**, 82, 87-93	4.5	149
291	Effects on health of air pollution: a narrative review. *Internal and Emergency Medicine*, **2015**, 10, 657-62	3.7	148
290	A common mutation in the methylenetetrahydrofolate reductase gene (C677T) increases the risk for deep-vein thrombosis in patients with mutant factor V (factor V:Q506). *Arteriosclerosis, Thrombosis, and Vascular Biology*, **1997**, 17, 1662-6	9.4	145
289	How I treat patients with von Willebrand disease. *Blood*, **2001**, 97, 1915-9	2.2	135
288	Multiple diseases and polypharmacy in the elderly: challenges for the internist of the third millennium. *Journal of Comorbidity*, **2011**, 1, 28-44	4	132
287	Thrombogenicity and cardiovascular effects of ambient air pollution. *Blood*, **2011**, 118, 2405-12	2.2	127
286	Purinoceptors on blood platelets: further pharmacological and clinical evidence to suggest the presence of two ADP receptors. *British Journal of Haematology*, **1995**, 91, 434-44	4.5	123
285	Association of anticholinergic burden with cognitive and functional status in a cohort of hospitalized elderly: comparison of the anticholinergic cognitive burden scale and anticholinergic risk scale: results from the REPOSI study. *Drugs and Aging*, **2013**, 30, 103-12	4.7	120
284	Back to the future: a recent history of haemophilia treatment. *Haemophilia*, **2008**, 14 Suppl 3, 10-8	3.3	114
283	Procoagulant imbalance in patients with non-alcoholic fatty liver disease. *Journal of Hepatology*, **2014**, 61, 148-54	13.4	113
282	SARS-CoV2 vertical transmission with adverse effects on the newborn revealed through integrated immunohistochemical, electron microscopy and molecular analyses of Placenta. *EBioMedicine*, **2020** , 59, 102951	8.8	108
281	Health status and quality of life of elderly persons with severe hemophilia born before the advent of modern replacement therapy. *Journal of Thrombosis and Haemostasis*, **2009**, 7, 780-6	15.4	107
280	Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial. *Blood*, **2013**, 122, 648-57	2.2	101
279	The bleeding score predicts clinical outcomes and replacement therapy in adults with von Willebrand disease. *Blood*, **2014**, 123, 4037-44	2.2	100
278	von Willebrand factor/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery. *Journal of Thrombosis and Haemostasis*, **2007**, 5, 1420-30	15.4	98
277	Multimorbidity and polypharmacy in the elderly: lessons from REPOSI. *Internal and Emergency Medicine*, **2014**, 9, 723-34	3.7	95
276	Short-term effects of air pollution on cardiovascular diseases: outcomes and mechanisms. *Journal of Thrombosis and Haemostasis*, **2007**, 5, 2169-74	15.4	93
275	Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients. *Journal of Thrombosis and Haemostasis*, **2007**, 5, 1115-24	15.4	90

274	Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with high-responding inhibitors. *Journal of Thrombosis and Haemostasis*, **2009**, 7, 1809-15	15.4	88
273	Desmopressin (DDAVP) in the treatment of bleeding disorders: the first twenty years. *Haemophilia*, **2000**, 6 Suppl 1, 60-7	3.3	88
272	Acquired haemophilia A: a 2013 update. *Thrombosis and Haemostasis*, **2013**, 110, 1114-20	7	85
271	Plasma levels of von Willebrand factor regulate ADAMTS-13, its major cleaving protease. *British Journal of Haematology*, **2004**, 126, 213-8	4.5	84
270	Co-morbidities and quality of life in elderly persons with haemophilia. *British Journal of Haematology*, **2010**, 148, 522-33	4.5	81
269	Air pollution and cardiovascular disease. *Thrombosis Research*, **2012**, 129, 230-4	8.2	76
268	The Effect of Desmopressin on Reducing Blood Loss in Cardiac Surgery A Meta-Analysis of Double-Blind, Placebo-Controlled Trials. *Thrombosis and Haemostasis*, **1995**, 74, 1064-1070	7	76
267	Von Willebrand factor cleaving protease (ADAMTS-13) in 123 patients with connective tissue diseases (systemic lupus erythematosus and systemic sclerosis). *Haematologica*, **2003**, 88, 914-8	6.6	76
266	Biochemical and Metabolic Aspects of Platelet Dysfunction in Chronic Myeloproliferative Disorders. *Thrombosis and Haemostasis*, **1982**, 47, 084-089	7	75
265	Clinical manifestations in 28 Italian and Iranian patients with severe factor VII deficiency. *Haemophilia*, **1997**, 3, 242-6	3.3	74
264	Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response. *Haemophilia*, **2007**, 13, 373-9	3.3	74
263	Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasma-product exposed toddlers). *Haemophilia*, **2007**, 13 Suppl 5, 65-8	3.3	74
262	Absence of antibodies to AIDS virus in haemophiliacs treated with heat-treated Factor VIII concentrate. *Lancet, The*, **1985**, 1, 271-2	40	74
261	Prophylaxis in severe forms of von Willebrand's disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN). *Haemophilia*, **2013**, 19, 76-81	3.3	72
260	Classic thrombophilic gene variants. *Thrombosis and Haemostasis*, **2015**, 114, 885-9	7	72
259	Thrombotic adverse events to coagulation factor concentrates for treatment of patients with haemophilia and von Willebrand disease: a systematic review of prospective studies. *Haemophilia*, **2012**, 18, e173-87	3.3	71
258	Italian Registry of Haemophilia and Allied Disorders. Objectives, methodology and data analysis. *Haemophilia*, **2008**, 14, 444-53	3.3	70
257	Clinical use of Haemate P in inherited von Willebrand's disease: a cohort study on 100 Italian patients. *Haematologica*, **2007**, 92, 944-51	6.6	67

256	Impact on human health of climate changes. *European Journal of Internal Medicine*, **2015**, 26, 1-5	3.9	66
255	Abnormal hemostasis tests and bleeding in chronic liver disease: are they related? No. *Journal of Thrombosis and Haemostasis*, **2006**, 4, 721-3	15.4	66
254	Clinical evaluation of viral safety of coagulation factor VIII and IX concentrates. *Vox Sanguinis*, **1993**, 64, 197-203	3.1	66
253	Deficiency of (33P)2MeS-ADP Binding Sites on Platelets with Secretion Defect, Normal Granule Stores and Normal Thromboxane A2 Production. *Thrombosis and Haemostasis*, **1997**, 77, 0986-0990	7	65
252	Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. *Blood*, **1997**, 90, 2515-21	2.2	65
251	Gender-differences in disease distribution and outcome in hospitalized elderly: data from the REPOSI study. *European Journal of Internal Medicine*, **2014**, 25, 617-23	3.9	62
250	Intravenous and Subcutaneous Administration of Desmopresssin (DDAVP) to Hemophiliacs: Pharmacokinetics and Factor VIII Responses. *Thrombosis and Haemostasis*, **1987**, 58, 1037-1039	7	62
249	Hemophilia therapy: the future has begun. *Haematologica*, **2020**, 105, 545-553	6.6	60
248	How we choose factor VIII to treat hemophilia. *Blood*, **2012**, 119, 4108-14	2.2	60
247	Pharmacokinetics of Monoclonally-Purified and Recombinant Factor VIII in Patients with Severe von Willebrand Disease. *Thrombosis and Haemostasis*, **1993**, 70, 270-272	7	54
246	Von Willebrand disease-associated angiodysplasia: a few answers, still many questions. *British Journal of Haematology*, **2013**, 161, 177-82	4.5	53
245	Subcutaneous desmopressin (DDAVP) shortens the bleeding time in uremia. *American Journal of Hematology*, **1989**, 31, 32-5	7.1	52
244	Evidence-based recommendations on the treatment of von Willebrand disease in Italy. *Blood Transfusion*, **2009**, 7, 117-26	3.6	51
243	Laboratory Screening of Inherited Thrombotic Syndromes. *Thrombosis and Haemostasis*, **1987**, 57, 247-251	7	51
242	Prevalence of potentially inappropriate medications and risk of adverse clinical outcome in a cohort of hospitalized elderly patients: results from the REPOSI Study. *Journal of Clinical Pharmacy and Therapeutics*, **2014**, 39, 511-5	2.2	50
241	Is haemophilia B less severe than haemophilia A?. *Haemophilia*, **2013**, 19, 499-502	3.3	49
240	Gastrointestinal angiodysplasia and bleeding in von Willebrand disease. *Thrombosis and Haemostasis*, **2014**, 112, 427-31	7	48
239	Under-detection of delirium and impact of neurocognitive deficits on in-hospital mortality among acute geriatric and medical wards. *European Journal of Internal Medicine*, **2015**, 26, 696-704	3.9	47

238	Hemostasis Abnormalities in Patients with Vascular Dementia and Alzheimer's Disease. *Thrombosis and Haemostasis*, **1996**, 75, 216-218	7	46
237	Novel evidence for a greater burden of ambient air pollution on cardiovascular disease. *Haematologica*, **2019**, 104, 2349-2357	6.6	45
236	Drug-drug interactions in a cohort of hospitalized elderly patients. *Pharmacoepidemiology and Drug Safety*, **2013**, 22, 1054-60	2.6	41
235	Subcutaneous Desmopressin (DDAVP) Shortens the Prolonged Bleeding Time in Patients with Liver Cirrhosis. *Thrombosis and Haemostasis*, **1990**, 64, 358-360	7	40
234	Inhibitor eradication with rituximab in haemophilia: where do we stand?. *British Journal of Haematology*, **2014**, 165, 600-8	4.5	39
233	Old and new anticoagulant drugs: a minireview. *Annals of Medicine*, **2011**, 43, 116-23	1.5	39
232	Risk of thromboembolic complications in patients with inflammatory bowel disease. Study of hemostasis measurements. *International Journal of Clinical and Laboratory Research*, **1991**, 21, 165-70		37
231	Hemostatic defects in liver and renal dysfunction. *Hematology American Society of Hematology Education Program*, **2012**, 2012, 168-173	3.1	37
230	Adverse Effects of Treatment with Porcine Factor VIII. *Thrombosis and Haemostasis*, **1991**, 65, 245-247	7	37
229	Defining Aging Phenotypes and Related Outcomes: Clues to Recognize Frailty in Hospitalized Older Patients. *Journals of Gerontology - Series A Biological Sciences and Medical Sciences*, **2017**, 72, 395-402	6.4	35
228	Venous thromboembolism in von Willebrand disease. *Thrombosis and Haemostasis*, **2002**, 88, 378-9	7	35
227	High Frequency of the C677T Mutation in the Methylenetetrahydrofolate Reductase (MTHFR) Gene in Northern Italy. *Thrombosis and Haemostasis*, **1997**, 78, 963-964	7	34
226	Polypharmacy in older people: lessons from 10 years of experience with the REPOSI register. *Internal and Emergency Medicine*, **2018**, 13, 1191-1200	3.7	32
225	Patients with localized and disseminated tumors have reduced but measurable levels of ADAMTS-13 (von Willebrand factor cleaving protease). *Haematologica*, **2003**, 88, 454-8	6.6	32
224	Genetic risk stratification to reduce inhibitor development in the early treatment of hemophilia A: a SIPPET analysis. *Blood*, **2017**, 130, 1757-1759	2.2	31
223	Association between particulate air pollution and venous thromboembolism: A systematic literature review. *European Journal of Internal Medicine*, **2016**, 27, 10-3	3.9	30
222	Treatment of von Willebrand disease. *Haemophilia*, **1998**, 4, 661-4	3.3	30
221	Modern Treatment of Hemophilia: From the Shadows Towards the Light. *Thrombosis and Haemostasis*, **1993**, 70, 017-023	7	29

220	Nonneutralizing antibodies against factor VIII and risk of inhibitor development in severe hemophilia A. *Blood*, **2017**, 129, 1245-1250	2.2	28
219	Mitigation of air pollution by greenness: A narrative review. *European Journal of Internal Medicine*, **2018**, 55, 1-5	3.9	28
218	von Willebrand factor contaminating porcine factor VIII concentrate (Hyate:C) causes platelet aggregation. *British Journal of Haematology*, **1986**, 63, 703-11	4.5	28
217	Efficacy and safety of highly purified, doubly virus-inactivated VWF/FVIII concentrates in inherited von Willebrand's disease: results of an Italian cohort study on 120 patients characterized by bleeding severity score. *Haemophilia*, **2010**, 16, 101-10	3.3	27
216	Familial Dysfunction of Protein S. *Thrombosis and Haemostasis*, **1989**, 62, 763-766	7	27
215	Von Willebrand factor (Vonvendi): the first recombinant product licensed for the treatment of von Willebrand disease. *Expert Review of Hematology*, **2016**, 9, 825-30	2.8	27
214	Half-life extension technologies for haemostatic agents. *Thrombosis and Haemostasis*, **2015**, 113, 165-767		26
213	Health-related quality of life and psychological well-being in elderly patients with haemophilia. *Haemophilia*, **2012**, 18, 345-52	3.3	26
212	Sustained correction of the bleeding time in an afibrinogenaemic patient after infusion of fresh frozen plasma. *British Journal of Haematology*, **1992**, 82, 388-90	4.5	26
211	Immune Status of Asymptomatic HIV-Infected Hemophiliacs: Randomized, Prospective, Two-Year Comparison of Treatment with a High-Purity or an Intermediate-Purity Factor VIII Concentrate. *Thrombosis and Haemostasis*, **1992**, 67, 310-313	7	26
210	Type I von Willebrand disease, subtype 'platelet low': decreased platelet adhesion can be explained by low synthesis of von Willebrand factor in endothelial cells. *British Journal of Haematology*, **1993**, 83, 88-93	4.5	25
209	Ndufc2 Gene Inhibition Is Associated With Mitochondrial Dysfunction and Increased Stroke Susceptibility in an Animal Model of Complex Human Disease. *Journal of the American Heart Association*, **2016**, 5,	6	25
208	Proteolysis of von Willebrand factor is decreased in acute promyelocytic leukaemia by treatment with all-trans-retinoic acid. *British Journal of Haematology*, **1996**, 92, 733-9	4.5	24
207	Fibrinogen Milano II: A Congenital Dysfibrinogenaemia Associated with Juvenile Arterial and Venous Thrombosis. *Thrombosis and Haemostasis*, **1986**, 55, 131-135	7	24
206	COVID-19 Vaccine and Death: Causality Algorithm According to the WHO Eligibility Diagnosis. *Diagnostics*, **2021**, 11,	3.8	24
205	Innovative Pharmacological Therapies for the Hemophilias Not Based on Deficient Factor Replacement. *Seminars in Thrombosis and Hemostasis*, **2016**, 42, 526-32	5.3	24
204	The complex differential diagnosis between thrombotic thrombocytopenic purpura and the atypical hemolytic uremic syndrome: Laboratory weapons and their impact on treatment choice and monitoring. *Thrombosis Research*, **2015**, 136, 851-4	8.2	22
203	Venous thrombosis and anticoagulant therapy. *British Journal of Haematology*, **2001**, 114, 258-70	4.5	22

202	Intramuscular anti-D immunoglobulins for home treatment of chronic immune thrombocytopenic purpura. *British Journal of Haematology*, **1992**, 80, 337-40	4.5	22
201	Liver disease, coagulopathies and transfusion therapy. *Blood Transfusion*, **2013**, 11, 32-6	3.6	22
200	Factor VIII replacement is still the standard of care in haemophilia A. *Blood Transfusion*, **2019**, 17, 479-486	3.6	22
199	Comparison of Functional Assays for Protein S: European Collaborative Study of Patients with Congenital and Acquired Deficiency. *Thrombosis and Haemostasis*, **1993**, 70, 0946-0950	7	22
198	Uncertain thrombophilia markers. *Thrombosis and Haemostasis*, **2016**, 115, 25-30	7	21
197	Antithrombin Milano, Single Amino Acid Substitution at the Reactive Site, Arg393 to Cys. *Thrombosis and Haemostasis*, **1988**, 60, 471-475	7	21
196	Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome. *Oncotarget*, **2016**, 7, 80083-80090	3.3	21
195	Low Levels of the Anticoagulant Activity of Protein C in Patients with Chronic Renal Insufficiency: an Inhibitor of Protein C Is Present in Uremic Plasma. *Thrombosis and Haemostasis*, **1991**, 66, 420-425	7	21
194	Antibody to Hepatitis G Mrus after a Vapour-Heated Factor Vlll Goncentrate. *Thrombosis and Haemostasis*, **1990**, 64, 232-234	7	21
193	Multicenter Comparison of Five Functional and Two Immunological Assays for Protein C. *Thrombosis and Haemostasis*, **1987**, 57, 044-048	7	21
192	SIPPET: methodology, analysis and generalizability. *Haemophilia*, **2017**, 23, 353-361	3.3	20
191	AIDS, hepatitis and hemophilia in the 1980s: memoirs from an insider. *Journal of Thrombosis and Haemostasis*, **2003**, 1, 2065-9	15.4	20
190	Post-mortem findings in vaccine-induced thrombotic thombocytopenia. *Haematologica*, **2021**, 106, 2291-2293	6.2	20
189	Atypical hemolytic uremic syndrome (aHUS): essential aspects of an accurate diagnosis. *Clinical Advances in Hematology and Oncology*, **2016**, 14 Suppl 11, 2-15	0.6	20
188	Acquired von Willebrand syndrome: focused for hematologists. *Haematologica*, **2020**, 105, 2032-2037	6.6	19
187	Progress in the contemporary management of hemophilia: The new issue of patient aging. *European Journal of Internal Medicine*, **2017**, 43, 16-21	3.9	18
186	Adherence to antibiotic treatment guidelines and outcomes in the hospitalized elderly with different types of pneumonia. *European Journal of Internal Medicine*, **2015**, 26, 330-7	3.9	18
185	Gender difference in drug use in hospitalized elderly patients. *European Journal of Internal Medicine* , **2015**, 26, 483-90	3.9	18

184	Red cells playing as activated platelets in thalassemia intermedia. *Journal of Thrombosis and Haemostasis*, **2010**, 8, 2149-51	15.4	18
183	Direct oral anticoagulants and venous thromboembolism. *European Respiratory Review*, **2016**, 25, 295-303	3.8	18
182	New therapies for von Willebrand disease. *Blood Advances*, **2019**, 3, 3481-3487	7.8	18
181	Miracle of haemophilia drugs: Personal views about a few main players. *Haemophilia*, **2018**, 24, 557-562	3.3	18
180	Venous thrombosis: the history of knowledge. *Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research*, **2002**, 32, 209-12		17
179	Patients with severe von Willebrand disease are insensitive to the releasing effect of DDAVP: evidence that the DDAVP-induced increase in plasma factor VIII is not secondary to the increase in plasma von Willebrand factor. *British Journal of Haematology*, **1994**, 86, 333-7	4.5	17
178	Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: a cross-over randomized trial. *Blood*, **1992**, 79, 3130-7	2.2	17
177	The Health and Economic Burden of Air Pollution. *American Journal of Medicine*, **2015**, 128, 931-2	2.4	16
176	Prescription drug use among older adults in Italy: a country-wide perspective. *Journal of the American Medical Directors Association*, **2014**, 15, 531.e11-531.e15	5.9	15
175	Prognostic value of estimated glomerular filtration rate in hospitalized elderly patients. *Internal and Emergency Medicine*, **2014**, 9, 735-47	3.7	15
174	The International Society for Thrombosis and Haemostasis owns its official journal: the future has begun!. *Journal of Thrombosis and Haemostasis*, **2003**, 1, 1-2	15.4	15
173	Type II H von Willebrand disease: new structural abnormality of plasma and platelet von Willebrand factor in a patient with prolonged bleeding time and borderline levels of ristocetin cofactor activity. *American Journal of Hematology*, **1989**, 32, 287-93	7.1	15
172	Prediction of factor VIII inhibitor development in the SIPPET cohort by mutational analysis and factor VIII antigen measurement. *Journal of Thrombosis and Haemostasis*, **2018**, 16, 778-790	15.4	14
171	Disability, and not diabetes, is a strong predictor of mortality in oldest old patients hospitalized with pneumonia. *European Journal of Internal Medicine*, **2018**, 54, 53-59	3.9	14
170	Management of Bleeding Associated with New Oral Anticoagulants. *Seminars in Thrombosis and Hemostasis*, **2015**, 41, 788-801	5.3	14
169	Coexistence of a novel homozygous nonsense mutation in exon 13 of the factor V gene with the homozygous Leiden mutation in two unrelated patients with severe factor V deficiency. *British Journal of Haematology*, **2001**, 114, 871-4	4.5	14
168	Oral anticoagulant use in octogenarian European patients with atrial fibrillation: A subanalysis of PREFER in AF. *International Journal of Cardiology*, **2017**, 232, 98-104	3.2	13
167	Relationship between atrial fibrillation and cognitive decline in individuals aged 80 and older. *European Journal of Internal Medicine*, **2017**, 46, 6-10	3.9	13

166	Management of antithrombotic therapy for acute coronary syndromes and atrial fibrillation in patients with hemophilia. *Expert Opinion on Pharmacotherapy*, **2012**, 13, 505-10	4	13
165	Resistance to activated protein C in unselected patients with arterial and venous thrombosis. *American Journal of Hematology*, **1997**, 55, 59-64	7.1	13
164	Oral Contraceptives Are a Risk Factor for Cerebral Vein Thrombosis. *Thrombosis and Haemostasis*, **1996**, 76, 477-478	7	13
163	Sex-Differences in the Pattern of Comorbidities, Functional Independence, and Mortality in Elderly Inpatients: Evidence from the RePoSI Register. *Journal of Clinical Medicine*, **2019**, 8,	5.1	13
162	Use of prophylaxis to prevent complications of hemophilia. *Advances in Experimental Medicine and Biology*, **2001**, 489, 59-64	3.6	13
161	Laboratory monitoring of replacement therapy for major surgery in von Willebrand disease. *Haemophilia*, **2017**, 23, 182-187	3.3	12
160	Understanding organ dysfunction in thrombotic thrombocytopenic purpura. *Intensive Care Medicine* , **2015**, 41, 715-8	14.5	12
159	Potentially Inappropriate Medications, Drug-Drug Interactions, and Anticholinergic Burden in Elderly Hospitalized Patients: Does an Association Exist with Post-Discharge Health Outcomes?. *Drugs and Aging*, **2020**, 37, 585-593	4.7	12
158	Need for randomized trials in hemophilia. *Journal of Thrombosis and Haemostasis*, **2006**, 4, 501-2	15.4	12
157	Gly319 --> arg substitution in the dysfunctional prothrombin Segovia. *British Journal of Haematology*, **1999**, 105, 667-9	4.5	12
156	Charge heterogeneity of human protein C revealed by isoelectric focusing in immobilized pH gradients. *Electrophoresis*, **1985**, 6, 373-376	3.6	12
155	Present and future challanges in the treatment of haemophilia: a clinician's perspective. *Blood Transfusion*, **2013**, 11 Suppl 4, s77-81	3.6	12
154	The Effect of Instrumentation on Thromboplastin Calibration. *Thrombosis and Haemostasis*, **1992**, 67, 588-589	7	12
153	Human Platelet Aggregation and Release Reaction Induced by Platelet Activating Factor (PAF-Acether) Effects of Acetylsalicylic Acid and External Ionized Calcium. *Thrombosis and Haemostasis*, **1985**, 53, 221-224	7	12
152	Ageing successfully with haemophilia: A multidisciplinary programme. *Haemophilia*, **2018**, 24, 57-62	3.3	12
151	Primary hyperfibrinolysis: Facts and fancies. *Thrombosis Research*, **2018**, 166, 71-75	8.2	11
150	The real value of thrombophilia markers in identifying patients at high risk of venous thromboembolism. *Expert Review of Hematology*, **2014**, 7, 757-65	2.8	11
149	Haematology clinic: Haemophilia A. *Hematology*, **2014**, 19, 181-2	2.2	11

148	von Willebrand disease in the 21st century: current approaches and new challenges. *Haemophilia*, **2009**, 15, 1154-8	3.3	11
147	Hemostatic defects in liver and renal dysfunction. *Hematology American Society of Hematology Education Program*, **2012**, 2012, 168-73	3.1	11
146	Prophylactic efficacy and pharmacokinetically guided dosing of a von Willebrand factor/factor VIII concentrate in adults and children with von Willebrand's disease undergoing elective surgery: a pooled and comparative analysis of data from USA and European Union clinical trials. *Blood Transfusion*, **2013**, 11, 533-40	3.6	11
145	Telemedicine and telerehabilitation: current and forthcoming applications in haemophilia. *Blood Transfusion*, **2019**, 17, 385-390	3.6	11
144	Monoclonal Antibodies Directed to the Calcium-Free Conformation of Human Protein S. *Thrombosis and Haemostasis*, **1989**, 62, 708-714	7	11
143	Electroblot and Immunoperoxidase Staining for Rapid Screening of the Abnormalities of the Multimeric Structure of von Willebrand Factor in von Willebrand Disease. *Thrombosis and Haemostasis*, **1986**, 55, 246-249	7	11
142	Tailoring hemostatic therapies to lower inhibitor development in previously untreated patients with severe hemophilia A. *Journal of Thrombosis and Haemostasis*, **2016**, 14, 1330-6	15.4	11
141	Drug-drug interactions involving CYP3A4 and p-glycoprotein in hospitalized elderly patients. *European Journal of Internal Medicine*, **2019**, 65, 51-57	3.9	10
140	Brain and kidney, victims of atrial microembolism in elderly hospitalized patients? Data from the REPOSI study. *European Journal of Internal Medicine*, **2015**, 26, 243-9	3.9	10
139	The never ending success story of tranexamic acid in acquired bleeding. *Haematologica*, **2020**, 105, 1201-1205	6.2	10
138	Novel investigations on the protective role of the FVIII/VWF complex in inhibitor development. *Haemophilia*, **2014**, 20 Suppl 6, 2-16	3.3	10
137	Thromboprophylaxis in the oldest old with atrial fibrillation: between Scylla and Charybdis. *European Journal of Internal Medicine*, **2013**, 24, 285-7	3.9	10
136	Investigational drugs for coagulation disorders. *Expert Opinion on Investigational Drugs*, **2013**, 22, 945-53	5.9	10
135	The safety of pharmacologic options for the treatment of persons with hemophilia. *Expert Opinion on Drug Safety*, **2016**, 15, 1391-400	4.1	10
134	Risk factors for three-month mortality after discharge in a cohort of non-oncologic hospitalized elderly patients: Results from the REPOSI study. *Archives of Gerontology and Geriatrics*, **2018**, 74, 169-173	4	9
133	Integrated postural analysis in children with haemophilia. *Haemophilia*, **2014**, 20, 263-7	3.3	9
132	Evolution of the European guidelines for the clinical development of factor VIII products: little progress towards improved patient management. *Haemophilia*, **2013**, 19, 344-8	3.3	9
131	Benefits and limitations of extended plasma half-life factor VIII products in hemophilia A. *Expert Opinion on Investigational Drugs*, **2020**, 29, 303-309	5.9	8

130	A contemporary look at FVIII inhibitor development: still a great influence on the evolution of hemophilia therapies. *Expert Review of Hematology*, **2018**, 11, 87-97	2.8	8
129	The role of natural VWF/FVIII complex concentrates in contemporary haemophilia care: a guideline for the next decade. *Haemophilia*, **2012**, 18 Suppl 2, 2-7	3.3	8
128	Mechanism of hemostasis defects and management of bleeding in patients with acute coronary syndromes. *European Journal of Internal Medicine*, **2010**, 21, 254-9	3.9	8
127	Autoimmune hemophilia at rescue. *Haematologica*, **2009**, 94, 459-61	6.6	8
126	Fine particulate: it matters. *Journal of Thrombosis and Haemostasis*, **2010**, 8, 659-61	15.4	8
125	Consistency of ADAMTS-13 activity assays: a moderately optimistic view. *Journal of Thrombosis and Haemostasis*, **2003**, 1, 1880-1	15.4	8
124	Pain and Frailty in Hospitalized Older Adults. *Pain and Therapy*, **2020**, 9, 727-740	3.6	8
123	Treatment of von Willebrand disease. *Thrombosis and Haemostasis*, **2001**, 86, 149-53	7	8
122	The stigma of low opioid prescription in the hospitalized multimorbid elderly in Italy. *Internal and Emergency Medicine*, **2015**, 10, 305-13	3.7	7
121	Comorbidities in persons with haemophilia aged 60 years or more compared with age-matched people from the general population. *Haemophilia*, **2018**, 24, e6-e10	3.3	7
120	Prognostic value of degree and types of anaemia on clinical outcomes for hospitalised older patients. *Archives of Gerontology and Geriatrics*, **2017**, 69, 21-30	4	7
119	Dosing anticoagulant therapy with coumarin drugs: is genotyping clinically useful? No. *Journal of Thrombosis and Haemostasis*, **2008**, 6, 1450-2	15.4	7
118	Thrombosis and bleeding disorders outside Western countries. *Journal of Thrombosis and Haemostasis*, **2007**, 5 Suppl 1, 68-72	15.4	7
117	The European standards of Haemophilia Centres. *Blood Transfusion*, **2014**, 12 Suppl 3, s525-30	3.6	7
116	B19 Parvovirus Withstands Super Heating In Antihemophilic Concentrates. *Thrombosis and Haemostasis*, **1996**, 76, 821-821	7	7
115	Comorbidity does not mean clinical complexity: evidence from the RePoSI register. *Internal and Emergency Medicine*, **2020**, 15, 621-628	3.7	7
114	Use and prescription appropriateness of drugs for peptic ulcer and gastrooesophageal reflux disease in hospitalized older people. *European Journal of Clinical Pharmacology*, **2020**, 76, 459-465	2.8	7
113	Pattern of comorbidities and 1-year mortality in elderly patients with COPD hospitalized in internal medicine wards: data from the RePoSI Registry. *Internal and Emergency Medicine*, **2021**, 16, 389-400	3.7	7

112	Improving primary care in Europe beyond COVID-19: from telemedicine to organizational reforms. *Internal and Emergency Medicine*, **2021**, 16, 255-258	3.7	7
111	Antipsychotic prescription and mortality in hospitalized older persons. *Psychogeriatrics*, **2017**, 17, 397-405	1.8	6
110	Involvement of the IgE-basophil system and mild complement activation in haemophilia B with anti-factor IX neutralizing antibodies and anaphylaxis. *Haemophilia*, **2017**, 23, e348-e353	3.3	6
109	Aging with Hemophilia: The Challenge of Appropriate Drug Prescription. *Mediterranean Journal of Hematology and Infectious Diseases*, **2019**, 11, e2019056	3.2	6
108	Pediatric requirements in Europe stymie help for hemophilia. *Nature Medicine*, **2014**, 20, 117	50.5	6
107	Treatment of haemophilia: building on strength in the third millennium. *Haemophilia*, **2011**, 17 Suppl 3, 1-24	3.3	6
106	Activated Partial Thromboplastin Time. *Scandinavian Journal of Haematology*, **2009**, 25, 308-317		6
105	Treatment of von Willebrand disease. *International Journal of Clinical and Laboratory Research*, **1998**, 28, 211-4		6
104	Desmopressin: an historical introduction. *Haemophilia*, **2008**, 14 Suppl 1, 1-4	3.3	6
103	Overview of bleeding in cancer patients. *Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research*, **2003**, 33 Suppl 1, 44-5		6
102	Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease. *British Journal of Haematology*, **2000**, 111, 1236-1239	4.5	6
101	The demand for factor VIII and for factor IX and the toll fractionation product surplus management. *Blood Transfusion*, **2013**, 11 Suppl 4, s64-76	3.6	6
100	Transfusion Requirements Are Correlated with the Degree of Proteolysis of von Willebrand Factor during Orthotopic Liver Transplantation. *Thrombosis and Haemostasis*, **1997**, 78, 813-819	7	6
99	Von Willebrand disease type 2N: An update. *Journal of Thrombosis and Haemostasis*, **2021**, 19, 909-916	15.4	6
98	Rate and appropriateness of polypharmacy in older patients with hemophilia compared with age-matched controls. *Haemophilia*, **2018**, 24, 726-732	3.3	5
97	Viral safety of plasma-derived and recombinant products used in the management of haemophilia A and B. *Haemophilia*, **1995**, 1 Suppl 1, 14-20	3.3	5
96	Dissociated antibody responses to the S and pre-S2 regions of the hepatitis B virus after vaccination in hemophiliacs. *Journal of Medical Virology*, **1989**, 28, 156-8	19.7	5
95	Choice of replacement therapy for hemophilia: recombinant products only?. *The Hematology Journal*, **2000**, 1, 72-6		5

94	Effects of Factor VIII Concentrates on the Immune System of Patients with Hemophilia. *Thrombosis and Haemostasis*, **1995**, 74, 437-439	7	5
93	Hemostatic Functions in Hypoalpha and Hyperbetalipoproteinemias. *Thrombosis and Haemostasis*, **1983**, 50, 624-625	7	5
92	Predictors of clinical events occurring during hospital stay among elderly patients admitted to medical wards in Italy. *European Journal of Internal Medicine*, **2016**, 32, 38-42	3.9	5
91	Efficacy and safety of a recombinant factor VIII produced from a human cell line (simoctocog alfa). *Expert Opinion on Drug Safety*, **2017**, 16, 405-410	4.1	4
90	Need for Deprescribing in Hospital Elderly Patients Discharged with a Limited Life Expectancy: The REPOSI Study. *Medical Principles and Practice*, **2019**, 28, 501-508	2.1	4
89	Traffic-related air pollution and the coronavirus pandemia: shadows and lights. *European Journal of Preventive Cardiology*, **2020**,	3.9	4
88	Prognostic relevance of glomerular filtration rate estimation obtained through different equations in hospitalized elderly patients. *European Journal of Internal Medicine*, **2018**, 54, 60-64	3.9	4
87	The importance of ABO blood group in pharmacokinetic studies in haemophilia A. *Haemophilia*, **2018**, 24, e122-e123	3.3	4
86	Management of Hemophilia in Older Patients. *Drugs and Aging*, **2017**, 34, 881-889	4.7	4
85	Emerging drugs for hemophilia B. *Expert Opinion on Emerging Drugs*, **2014**, 19, 407-14	3.7	4
84	Recombinant factor VIIa as haemostatic therapy in advanced liver disease. *Blood Transfusion*, **2013**, 11, 487-90	3.6	4
83	The increased demand for plasma-derived factor VIII in Italy. *Blood Transfusion*, **2017**, 15, 279-280	3.6	4
82	Combined Use of DNA Probes in First-Trimester Prenatal Diagnosis of Hemophilia A. *Thrombosis and Haemostasis*, **1987**, 58, 988-992	7	4
81	Repeated Release of the Tissue Factor Pathway Inhibitor. *Thrombosis and Haemostasis*, **1994**, 72, 327-328	7	4
80	Very Low Frequency of Normandy Type Mutations among Type 1 von Willebrand Disease Families. *Thrombosis and Haemostasis*, **1995**, 73, 324-324	7	4
79	Sustainable and personalized nutrition: From earth health to public health. *European Journal of Internal Medicine*, **2021**, 86, 12-16	3.9	4
78	The Use of Plasma-Derived Concentrates200-206		4
77	Reply to the letter by Iorio. *Haemophilia*, **2017**, 23, e248-e249	3.3	3

76	Viral safety of coagulation factor concentrates: memoirs from an insider. *Journal of Thrombosis and Haemostasis*, **2018**, 16, 630-633	15.4	3
75	Polypharmacy in older adults with severe haemophilia. *Haemophilia*, **2018**, 24, e1-e3	3.3	3
74	Defensive medicine: Everything and its opposite. *European Journal of Internal Medicine*, **2020**, 74, 117-118	3.9	3
73	Frequency of Factor V Arg506 Gin in Italians. *Thrombosis and Haemostasis*, **1996**, 75, 694-694	7	3
72	Risk of Inhibitor Development after Intermediate Purity Coagulation Factor Concentrates: Is It Truly Low?. *Thrombosis and Haemostasis*, **1995**, 74, 997-997	7	3
71	New therapies for von Willebrand disease. *Hematology American Society of Hematology Education Program*, **2019**, 2019, 590-595	3.1	3
70	Pharmacist-driven medication recognition/ reconciliation in older medical patients. *European Journal of Internal Medicine*, **2021**, 83, 39-44	3.9	3
69	Clinical factors associated with death in 3044 COVID-19 patients managed in internal medicine wards in Italy: comment. *Internal and Emergency Medicine*, **2021**, 1	3.7	3
68	The Molecular Basis of Von Willebrand Disease233-245		3
67	Conflicts of interest in medicine: a never-ending story. *Internal and Emergency Medicine*, **2020**, 15, 357-359	3.7	2
66	Direct oral anticoagulants and cirrhosis: More evidence still needed for efficacy and safety in portal vein thrombosis. *Vascular Pharmacology*, **2019**, 113, 92-93	5.9	2
65	Reply to: The importance and challenge of pediatric trials of hemophilia drugs. *Nature Medicine*, **2014**, 20, 466	50.5	2
64	Vaccine-induced immune thrombotic thrombocytopenia with atypical vein thrombosis: Implications for clinical practice.. *Phlebology*, **2022**, 2683555211068948	2	2
63	Cardiovascular health and ambient air pollution: lower is not enough. *European Journal of Preventive Cardiology*, **2020**,	3.9	2
62	A certification/accreditation model for Haemophilia Centres in Italy. *Blood Transfusion*, **2014**, 12 Suppl 3, s505-9	3.6	2
61	Prophylactic management of patients with von Willebrand disease.. *Therapeutic Advances in Hematology*, **2021**, 12, 20406207211064064	5.7	2
60	Restriction of Polymerase Chain Reaction Products for Carrier. *Thrombosis and Haemostasis*, **1990**, 63, 527-528	7	2
59	Fibrin(ogen) Peptides in Early Breast Cancer. *Thrombosis and Haemostasis*, **1989**, 62, 819	7	2

58	Preliminary In Vivo Evaluation of a Nanofiltered Factor IX Concentrate. *Thrombosis and Haemostasis* , **1995**, 73, 737-738	7	2
57	Characterization of an Abnormal Antithrombin (Milano 2) with Defective Thrombin Binding. *Thrombosis and Haemostasis*, **1986**, 56, 349-352	7	2
56	Hyperglycemia at admission, comorbidities, and in-hospital mortality in elderly patients hospitalized in internal medicine wards: data from the RePoSI Registry. *Acta Diabetologica*, **2021**, 58, 1225-1236	3.9	2
55	Therapeutic Duplicates in a Cohort of Hospitalized Elderly Patients: Results from the REPOSI Study. *Drugs and Aging*, **2016**, 33, 647-54	4.7	2
54	Intelligent game engines for home exercises (exergames) in boys with haemophilia. *Haemophilia*, **2021**, 27, e151-e154	3.3	2
53	Thrombotic thrombocytopenic purpura: a simpler diagnosis at last?. *Thrombosis and Haemostasis*, **1999**, 82, 1380-1	7	2
52	More on air pollution and venous thromboembolism. *European Journal of Internal Medicine*, **2017**, 37, e11	3.9	1
51	Appropriateness of antithrombotic prophylaxis in the oldest old with non-valvular atrial fibrillation: ARAPACIS and REPOSI. *European Journal of Internal Medicine*, **2015**, 26, e47-8	3.9	1
50	Gout, allopurinol intake and clinical outcomes in the hospitalized multimorbid elderly. *European Journal of Internal Medicine*, **2014**, 25, 847-52	3.9	1
49	Use of non-steroidal anti-inflammatory drugs and analgesics in a cohort of hospitalized elderly patients: Results from the REPOSI study. *European Journal of Internal Medicine*, **2017**, 38, e11-e12	3.9	1
48	Getting rid of refractory hemophilia. *Blood*, **2012**, 119, 1326-7	2.2	1
47	Aspirin as antiplatelet agent in diabetes: Cons. *European Journal of Internal Medicine*, **2010**, 21, 154-6	3.9	1
46	Partial inhibition of platelet aggregation by nebulized pentamidine in severe haemophiliacs. *Haemophilia*, **1997**, 3, 31-4	3.3	1
45	Reply:. *Hepatology*, **2007**, 45, 832-833	11.2	1
44	A novel two base pair deletion in the factor V gene associated with severe factor V deficiency. *British Journal of Haematology*, **2000**, 111, 1240-1246	4.5	1
43	The knowledge and perception of factor concentrate in persons with haemophilia A. *Haemophilia*, **1995**, 1, 232-5	3.3	1
42	Histological and immunohistochemical findings in a fatal case of thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination.. *Pathology Research and Practice*, **2022**, 231, 153796	3.4	1
41	The methodology for defining the European standards for the certification of Haemophilia Centres in Europe. *Blood Transfusion*, **2014**, 12 Suppl 3, s519-24	3.6	1

40	Comparison of quality of life, and emotional and functional profiles in older people with and without severe haemophilia. *Haemophilia*, **2021**, 27, e525-e529	3.3	1
39	The dark age of Italian general practice research - An Italian matter. *European Journal of Internal Medicine*, **2020**, 73, 98-99	3.9	1
38	Performance of a clinical risk prediction model for inhibitor formation in severe haemophilia A. *Haemophilia*, **2021**, 27, e441-e449	3.3	1
37	Bleeding Disorders in Primary Fibrinolysis. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	1
36	Community and hospital pharmacists in Europe: encroaching on medicine?. *Internal and Emergency Medicine*, **2021**, 16, 7-10	3.7	1
35	Authors' Reply to Brunetti et al. "Potentially Inappropriate Medications, Drug-Drug Interactions, and Anticholinergic Burden in Elderly Hospitalized Patients: Does an Association Exist with Post-Discharge Health Outcomes?". *Drugs and Aging*, **2021**, 38, 93-94	4.7	1
34	IgG subclasses as biomarkers for persistence of factor VIII inhibitors in previously untreated patients with severe haemophilia A. *British Journal of Haematology*, **2021**, 192, 621-625	4.5	1
33	Use of Lipid-Lowering Drugs and Associated Outcomes According to Health State Profiles in Hospitalized Older Patients. *Clinical Interventions in Aging*, **2021**, 16, 1251-1264	4	1
32	Treatment of von Willebrand's disease. *Journal of Internal Medicine Supplement*, **1997**, 740, 129-32		1
31	Pharmaceutical pricing in Europe: time to take the right direction.. *Internal and Emergency Medicine*, **2022**, 1	3.7	1
30	Pharmaceutical patenting in the European Union: reform or riddance. *Internal and Emergency Medicine*, **2021**, 1	3.7	0
29	ADAMTS13 Content of Plasma-Derived Factor VIII-Von Willebrand Factor Concentrates. *Blood*, **2012** , 120, 3383-3383	2.2	0
28	Perspective - The case for zero bleeds and drug bioequivalence in the treatment of congenital hemophilia A in 2021. *Blood Reviews*, **2021**, 50, 100849	11.1	0
27	The multifaceted spectrum of liver cirrhosis in older hospitalised patients: analysis of the REPOSI registry. *Age and Ageing*, **2021**, 50, 498-504	3	0
26	Clinical risk scores for the early prediction of severe outocomes in patients hospitalized for COVID-19: comment. *Internal and Emergency Medicine*, **2021**, 1	3.7	0
25	Thrombotic thrombocytopenic purpura and other immune-mediated blood disorders following vaccination against SARS-CoV-2.. *Haematologica*, **2022**, 107, 785-786	6.6	0
24	Integrated care: easy in theory, harder in practice?. *Internal and Emergency Medicine*, **2021**, 1	3.7	0
23	Gene transfer in hemophilia A: not cogent yet **2022**, 1, 7-8		0

22	Introduction and overview. *Blood Reviews*, **2015**, 29 Suppl 1, S1-3	11.1
21	Factor VIII Deficiency or Hemophilia A: Clinical Bleeding and Management **2014**, 45-56	
20	Clinical governance: many fancies, very few facts. *Internal and Emergency Medicine*, **2012**, 7, 3-4	3.7
19	Making clinical decisions on the basis of RODIN. *Haemophilia*, **2014**, 20, e174-5	3.3
18	William Hewson and the blood which issued last but clotted first: the beginning of the story of desmopressin in haemophilia and vWD. *Haemophilia*, **1996**, 2, 180-3	3.3
17	Spontaneous platelet aggregation during pregnancy in a patient with von Willebrand disease type IIB can be blocked by monoclonal antibodies to both platelet glycoproteins Ib and IIb/IIIa. *British Journal of Haematology*, **2008**, 75, 86-91	4.5
16	Ilsley Ingram. *Journal of Thrombosis and Haemostasis*, **2004**, 2, 1219-1219	15.4
15	Thrombolytic therapy in acute myocardial infarction. *Journal of Thrombosis and Haemostasis*, **2005**, 3, 2806-7	15.4
14	The risk of venous thromboembolism in family members with mutations in the genes of factor V or prothrombin or both. *British Journal of Haematology*, **2000**, 111, 1223-1229	4.5
13	Aspects of the clinical management of hereditary thrombophilia: a personal perspective. *Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research*, **2000**, 30 Suppl 2, 11-5	
12	Treatment of von Willebrand Disease. *Hematology*, **1998**, 3, 339-46	2.2
11	Antiplatelet Agents in Acute Myocardial Infarction and in the Post-infarction Period. *Platelets*, **1993**, 4, 24-5	3.6
10	EVALUATION OF A FULLY AUTOMATED CENTRIFUGAL ANALYSER FOR ITS PERFORMANCE OF HEMOSTASIS TESTS **1987**, 58, 0457	
9	Localization and Function of Platelet ADAMTS-13.. *Blood*, **2005**, 106, 3967-3967	2.2
8	Non-Sense-Mediated mRNA Decay in ADAMTS13 Gene Caused by 29 Nucleotide Deletion.. *Blood*, **2006**, 108, 1061-1061	2.2
7	Understanding hemostasis and thrombosis : The lesson learnt from natural models. *Japanese Journal of Thrombosis and Hemostasis*, **2008**, 19, 85-91	0
6	Rate of Inhibitor Development in Hemophilia A Patients Treated with Plasma Derived or Recombinant Factor VIII Concentrates. A Systematic Review of the Literature.. *Blood*, **2009**, 114, 3154-3154	2.2
5	Fibrinogens Milano II and Naples *Thrombosis and Haemostasis*, **1987**, 57, 375-375	7

4	What changed in the Italian internal medicine and geriatric wards during the lockdown. *European Journal of Internal Medicine*, **2021**, 84, 97-100	3.9
3	The search for the causes of myocardial infarction. Introduction. *Italian Heart Journal: Official Journal of the Italian Federation of Cardiology*, **2001**, 2, 489	
2	Autoimmune bleeding disorders in cancer patients. *Haemostasis*, **2001**, 31 Suppl 1, 45-6	
1	An ecological alliance against air pollution and cardiovascular disease **2022**, 1, 19-23	